Published May 2014
| public
Journal Article
Targeted Gene Therapy in the Treatment of X-Linked Hyper-lgM Syndrome
Abstract
X-linked hyper-IgM syndrome (XHIM) is a primary immunodeficiency with absent IgG, IgA, IgE and normal/elevated IgM due to defects in the CD40 ligand (CD40L) gene. CD40L is expressed on T-lymphocytes and is essential in the interaction between B and T cells that induces class switch recombination.
Additional Information
© 2014 Amencan Society of Gene & Cell Therapy. Session: Poster Session: Gene Targeting and Gene Correction I (5:30 PM-7:30 PM) Date/Time: Wednesday, May 21, 2014 - 5:30 PM Room: Hall A and B SouthAdditional details
- Eprint ID
- 47322
- Resolver ID
- CaltechAUTHORS:20140718-100633318
- Created
-
2014-07-18Created from EPrint's datestamp field
- Updated
-
2020-03-09Created from EPrint's last_modified field